



(11) **EP 1 727 809 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Bibliography INID code(s) 84

(48) Corrigendum issued on:
29.10.2008 Bulletin 2008/44

(45) Date of publication and mention
of the grant of the patent:
11.06.2008 Bulletin 2008/24

(21) Application number: **05706819.9**

(22) Date of filing: **09.03.2005**

(51) Int Cl.:
C07D 295/12 ^(2006.01) **C07D 265/06** ^(2006.01)
C07D 279/12 ^(2006.01) **C07D 417/04** ^(2006.01)
A61K 31/4406 ^(2006.01) **A61K 31/541** ^(2006.01)
A61K 31/5355 ^(2006.01) **A61P 25/22** ^(2006.01)

(86) International application number:
PCT/DK2005/000159

(87) International publication number:
WO 2005/087754 (22.09.2005 Gazette 2005/38)

(54) **SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES**

SUBSTITUIERTE MORPHOLIN- UND THIOMORPHOLINDERIVATE

DERIVÉS DE MORPHOLINE ET DE THIOMORPHOLINE SUBSTITUÉS

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR LV MK YU

(30) Priority: **12.03.2004 DK 200400412**
12.03.2004 US 552574 P

(43) Date of publication of application:
06.12.2006 Bulletin 2006/49

(60) Divisional application:
08007169.9 / 1 947 093

(73) Proprietor: **H. Lundbeck A/S**
2500 Valby-Copenhagen (DK)

(72) Inventors:
• **WENZEL TORNØE, Christian**
DK-2300 Copenhagen S (DK)
• **ROTTLÄNDER, Mario**
DK-2670 Greve (DK)

- **KHANZHIN, Nikolay**
DK-3050 Humlebaek (DK)
- **RITZÉN, Andreas**
DK-2720 Vanløse (DK)
- **WATSON, William Patrick**
DK-2720 Vanløse (DK)

(56) References cited:
WO-A-02/49628 **WO-A-02/066036**
US-A1- 2001 049 444

- **MAIN M J ET AL: "MODULATION OF KCNQ2/3 POTASSIUM CHANNELS BY THE NOVEL ANTICONVULSANT RETIGABINE" MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 58, no. 2, August 2000 (2000-08), pages 253-262, XP000972245 ISSN: 0026-895X**
- **DATABASE BEILSTEIN BEILSTEIN CROSSFIRE INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, DE; BRN 6233316 1993, XP002330358 & VERMA M AL: ARCH PHARM (WEINHEIM W GER), vol. 315, no. 7, 1982, pages 358-363,**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).